Ph-like ALL with ABL-class rearrangements (ABL1, ABL2, CSF1R, or PDGFRB) are sensitive to tyrosine kinase inhibition with imatinib and dasatinib, and these have been integrated in completed and ongoing trials, such as COG AALL1131 (NCT02883049), St. Here, ABL1 is linked to acute lymphoblastic leukemia.